| Year |
Citation |
Score |
| 2015 |
Lloyd SA, Morony SE, Ferguson VL, Simske SJ, Stodieck LS, Warmington KS, Livingston EW, Lacey DL, Kostenuik PJ, Bateman TA. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice. Bone. PMID 26318907 DOI: 10.1016/J.Bone.2015.08.021 |
0.598 |
|
| 2015 |
Bolon B, Grisanti M, Villasenor K, Morony S, Feige U, Simonet WS. Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice Veterinary Pathology. 52: 873-882. PMID 26018435 DOI: 10.1177/0300985815586221 |
0.52 |
|
| 2012 |
Morony S, Sage AP, Corbin T, Lu J, Tintut Y, Demer LL. Enhanced mineralization potential of vascular cells from SM2α-rankltg mice Calcified Tissue International. 91: 379-386. PMID 23052229 DOI: 10.1007/S00223-012-9655-9 |
0.659 |
|
| 2011 |
Henley C, Yang Y, Davis J, Lu JY, Morony S, Fan W, Florio M, Sun B, Shatzen E, Pretorius JK, Richards WG, St Jean DJ, Fotsch C, Reagan JD. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. The Journal of Pharmacology and Experimental Therapeutics. 337: 681-91. PMID 21422163 DOI: 10.1124/Jpet.110.178681 |
0.323 |
|
| 2009 |
Babij P, Roudier M, Graves T, Han CY, Chhoa M, Li CM, Juan T, Morony S, Grisanti M, Li X, Yu L, Dwyer D, Lloyd DJ, Bass MB, Richards WG, et al. New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 1552-64. PMID 19419305 DOI: 10.1359/Jbmr.090417 |
0.424 |
|
| 2009 |
Allen DL, Bandstra ER, Harrison BC, Thorng S, Stodieck LS, Kostenuik PJ, Morony S, Lacey DL, Hammond TG, Leinwand LL, Argraves WS, Bateman TA, Barth JL. Effects of spaceflight on murine skeletal muscle gene expression. Journal of Applied Physiology (Bethesda, Md. : 1985). 106: 582-95. PMID 19074574 DOI: 10.1152/Japplphysiol.90780.2008 |
0.302 |
|
| 2009 |
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 578-88. PMID 19049336 DOI: 10.1359/Jbmr.081206 |
0.566 |
|
| 2009 |
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 182-95. PMID 19016581 DOI: 10.1359/Jbmr.081112 |
0.58 |
|
| 2008 |
Lloyd SA, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S, Stolina M, Asuncion FJ, Bateman TA. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcified Tissue International. 82: 361-72. PMID 18465074 DOI: 10.1007/S00223-008-9133-6 |
0.576 |
|
| 2008 |
Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, ... Morony S, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 23: 860-9. PMID 18269310 DOI: 10.1359/Jbmr.080216 |
0.557 |
|
| 2008 |
Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation. 117: 411-20. PMID 18172035 DOI: 10.1161/Circulationaha.107.707380 |
0.574 |
|
| 2008 |
Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clinical & Experimental Metastasis. 25: 119-29. PMID 18064531 DOI: 10.1007/S10585-007-9127-1 |
0.537 |
|
| 2008 |
Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 19: 625-35. PMID 18038244 DOI: 10.1007/S00198-007-0509-7 |
0.553 |
|
| 2008 |
Morony S, Dwyer D, Stolina M, Kostenuik PJ, Tintut Y, Zhang Z, Demer LL, Cattley RC, Van G. Response to letter regarding article, "Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (-'-) mice" Circulation. 118: e19. DOI: 10.1161/Circulationaha.108.782649 |
0.56 |
|
| 2007 |
Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, et al. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 22: 1534-47. PMID 17576164 DOI: 10.1359/Jbmr.070616 |
0.541 |
|
| 2007 |
Huang MS, Morony S, Lu J, Zhang Z, Bezouglaia O, Tseng W, Tetradis S, Demer LL, Tintut Y. Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. The Journal of Biological Chemistry. 282: 21237-43. PMID 17522049 DOI: 10.1074/Jbc.M701341200 |
0.652 |
|
| 2007 |
Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong Y, Schreiber M, Dixon SJ, Sims SM, et al. Can osteoclasts be excluded? (Reply) Nature. 445: E19-E20. DOI: 10.1038/Nature05658 |
0.519 |
|
| 2006 |
Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 39: 754-66. PMID 16730481 DOI: 10.1016/J.Bone.2006.03.017 |
0.586 |
|
| 2006 |
Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440: 692-6. PMID 16572175 DOI: 10.1038/Nature04524 |
0.386 |
|
| 2006 |
Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan H-, Dunstan C, Lacey D, Martin D. The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism Calcified Tissue International. 78: 35-44. PMID 16362459 DOI: 10.1007/S00223-005-0161-1 |
0.526 |
|
| 2005 |
Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ. The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy Endocrinology. 146: 3235-3243. PMID 15845617 DOI: 10.1210/En.2004-1583 |
0.498 |
|
| 2005 |
Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Manuokian R, et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut. 54: 78-86. PMID 15591508 DOI: 10.1136/Gut.2003.035113 |
0.405 |
|
| 2004 |
Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice Bone. 34: 656-664. PMID 15050896 DOI: 10.1016/J.Bone.2003.12.006 |
0.544 |
|
| 2004 |
Bolon B, Morony S, Cheng Y, Hu YL, Feige U. Osteoclast Numbers in Lewis Rats with Adjuvant-induced Arthritis: Identification of Preferred Sites and Parameters for Rapid Quantitative Analysis Veterinary Pathology. 41: 30-36. PMID 14715965 DOI: 10.1354/Vp.41-1-30 |
0.44 |
|
| 2004 |
Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arteriosclerosis, Thrombosis, and Vascular Biology. 24: e6-10. PMID 14670933 DOI: 10.1161/01.Atv.0000112023.62695.7F |
0.682 |
|
| 2003 |
Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research. 18: 852-858. PMID 12733724 DOI: 10.1359/Jbmr.2003.18.5.852 |
0.474 |
|
| 2003 |
Pecaut MJ, Nelson GA, Peters LL, Kostenuik PJ, Bateman TA, Morony S, Stodieck LS, Lacey DL, Simske SJ, Gridley DS. Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. I. Immune population distributions. Journal of Applied Physiology (Bethesda, Md. : 1985). 94: 2085-94. PMID 12514166 DOI: 10.1152/Japplphysiol.01052.2002 |
0.432 |
|
| 2003 |
Gridley DS, Nelson GA, Peters LL, Kostenuik PJ, Bateman TA, Morony S, Stodieck LS, Lacey DL, Simske SJ, Pecaut MJ. Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. II. Activation, cytokines, erythrocytes, and platelets. Journal of Applied Physiology (Bethesda, Md. : 1985). 94: 2095-103. PMID 12506046 DOI: 10.1152/Japplphysiol.01053.2002 |
0.337 |
|
| 2002 |
Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis Arthritis and Rheumatism. 46: 3121-3135. PMID 12483715 DOI: 10.1002/Art.10680 |
0.548 |
|
| 2001 |
Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats Endocrinology. 142: 4295-4304. PMID 11564687 DOI: 10.1210/Endo.142.10.8437 |
0.478 |
|
| 2001 |
Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Molecular Therapy. 3: 197-205. PMID 11237676 DOI: 10.1006/Mthe.2001.0245 |
0.538 |
|
| 2001 |
Bolon B, Carter C, Daris M, Morony S, Campagnuolo G, Feige U, Sheng J. Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease Arthritis Research & Therapy. 3: 5. DOI: 10.1186/Ar371 |
0.562 |
|
| 2001 |
Feige U, Hu Y, Morony S, Campagnuolo G, Duryea D, Bolon B. OP0016 Osteoclast numbers in joints of rats with adjuvant arthritis are decreased by treatment with il-1ra and/or peg stnf-ri Annals of the Rheumatic Diseases. 60. DOI: 10.1136/Annrheumdis-2001.1025 |
0.417 |
|
| 2000 |
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis Journal of Experimental Medicine. 192: 463-474. PMID 10952716 DOI: 10.1084/Jem.192.4.463 |
0.504 |
|
| 2000 |
Li J, Sarosi I, Yan X, Morony S, Capparelli C, Tan H, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan S, Sun Y, Tarpley J, Martin L, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proceedings of the National Academy of Sciences of the United States of America. 97: 1566-1571. PMID 10677500 DOI: 10.1073/Pnas.97.4.1566 |
0.591 |
|
| 1999 |
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402: 304-9. PMID 10580503 DOI: 10.1038/46303 |
0.5 |
|
| 1999 |
Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR. A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3 Journal of Bone and Mineral Research. 14: 1478-1485. PMID 10469275 DOI: 10.1359/Jbmr.1999.14.9.1478 |
0.559 |
|
| 1999 |
Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes & Development. 13: 1015-24. PMID 10215628 DOI: 10.1101/Gad.13.8.1015 |
0.442 |
|
| 1999 |
Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, ... ... Morony S, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proceedings of the National Academy of Sciences of the United States of America. 96: 3540-3545. PMID 10097072 DOI: 10.1073/Pnas.96.7.3540 |
0.515 |
|
| 1999 |
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397: 315-23. PMID 9950424 DOI: 10.1038/16852 |
0.353 |
|
| 1998 |
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes & Development. 12: 1260-1268. PMID 9573043 DOI: 10.1101/Gad.12.9.1260 |
0.571 |
|
| Show low-probability matches. |